PZH2108

PZH2108 is an investigational, orally bioavailable small molecule pan-Trk (tropomyosin receptor kinase) inhibitor developed by Zhangzhou Pientzehuang Pharmaceutical. It is specifically designed to target the Trk family of receptors, including TrkA, TrkB, and TrkC, which are key mediators in the neurotrophin signaling pathway. This pathway, particularly the interaction between nerve growth factor (NGF) and TrkA, is a well-validated target for the management of chronic and inflammatory pain associated with malignancies. PZH2108 is being developed for the treatment of cancer-related bone pain in patients with bone metastases, multiple myeloma, and primary bone tumors. By inhibiting Trk signaling, the drug aims to disrupt the transmission and sensitization of pain signals in the bone microenvironment. It is currently undergoing Phase IIa clinical evaluation in China as an adjunct to stable background analgesic therapy.